Skip directly to search Skip directly to A to Z list Skip directly to navigation Skip directly to page options Skip directly to site content

Search PHGKB:

Last Posted: May 25, 2023
spot light Highlights

Wearable devices: underrepresentation in the ageing society
TW Guu et al, The Lancet Digital Health, June 2023

Wearable devices and smartphone applications could help health-care professionals gain insight into the spectrum of dementia conditions in a real-time, longitudinal, and more objective manner. Well validated devices and algorithms have the potential to assist in tracking cognitive and functional trajectories, monitoring social behaviour changes, preventing falls, and potentially relieving care-giver burden.

Emerging sensing and modeling technologies for wearable and cuffless blood pressure monitoring.
Lei Zhao et al. NPJ Digit Med 2023 5 (1) 93

Cardiovascular diseases (CVDs) are a leading cause of death worldwide. For early diagnosis, intervention and management of CVDs, it is highly desirable to frequently monitor blood pressure (BP), a vital sign closely related to CVDs, during people’s daily life, including sleep time. Towards this end, wearable and cuffless BP extraction methods have been extensively researched in recent years as part of the mobile healthcare initiative. This review focuses on the enabling technologies for wearable and cuffless BP monitoring platforms, covering both the emerging flexible sensor designs and BP extraction algorithms.

Digital health technology in clinical trials.
Mirja Mittermaier et al. NPJ Digit Med 2023 5 (1) 88

Digital health technologies (DHTs) have brought several significant improvements to clinical trials, enabling real-world data collection outside of the traditional clinical context and more patient-centered approaches. DHTs, such as wearables, allow the collection of unique personal data at home over a long period. But DHTs also bring challenges, such as digital endpoint harmonization and disadvantaging populations already experiencing the digital divide.

Circadian rhythm biomarker from wearable device data is related to concurrent antidepressant treatment response
FZ Ali et al, NPJ Digital Medicine, April 29, 2023

40 participants with MDD provided actigraphy data using wearable devices for one week after initiating antidepressant treatment in a randomized, double-blind, placebo-controlled trial. Their depression severity was calculated pretreatment, after one week and eight weeks of treatment. This study assesses the relationship between parametric and nonparametric measures of circadian rhythm and change in depression. Results show significant association between a lower circadian quotient (reflecting less robust rhythmicity) and improvement in depression from baseline following first week of treatment.

Search Result Summary

Disclaimer: Articles listed in the Public Health Genomics and Precision Health Knowledge Base are selected by the CDC Office of Public Health Genomics to provide current awareness of the literature and news. Inclusion in the update does not necessarily represent the views of the Centers for Disease Control and Prevention nor does it imply endorsement of the article's methods or findings. CDC and DHHS assume no responsibility for the factual accuracy of the items presented. The selection, omission, or content of items does not imply any endorsement or other position taken by CDC or DHHS. Opinion, findings and conclusions expressed by the original authors of items included in the update, or persons quoted therein, are strictly their own and are in no way meant to represent the opinion or views of CDC or DHHS. References to publications, news sources, and non-CDC Websites are provided solely for informational purposes and do not imply endorsement by CDC or DHHS.